Patriot Financial Group Insurance Agency LLC raised its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 16.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,000 shares of the biopharmaceutical company’s stock after buying an additional 1,700 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Dynavax Technologies Corporation were worth $108,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Teachers Advisors LLC raised its stake in Dynavax Technologies Corporation by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 5,618 shares during the period. Nationwide Fund Advisors raised its position in shares of Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 2,786 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Dynavax Technologies Corporation by 61.7% in the first quarter. Russell Investments Group Ltd. now owns 125,059 shares of the biopharmaceutical company’s stock worth $744,000 after buying an additional 47,735 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Dynavax Technologies Corporation by 30.0% in the first quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 9,634 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its position in shares of Dynavax Technologies Corporation by 90.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 1,098,510 shares of the biopharmaceutical company’s stock worth $6,536,000 after buying an additional 521,310 shares during the last quarter. Institutional investors own 60.23% of the company’s stock.

Dynavax Technologies Corporation (NASDAQ DVAX) opened at 17.00 on Wednesday. The stock has a 50 day moving average of $13.47 and a 200-day moving average of $8.01. Dynavax Technologies Corporation has a one year low of $3.20 and a one year high of $19.60. The company’s market cap is $930.70 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same quarter last year, the firm posted ($0.75) EPS. On average, equities analysts predict that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/30/patriot-financial-group-insurance-agency-llc-acquires-1700-shares-of-dynavax-technologies-corporation-dvax.html.

A number of brokerages have recently commented on DVAX. Cowen and Company reissued an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Monday, July 10th. BidaskClub lowered shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. William Blair reissued an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $6.00 to $27.00 in a report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation presently has a consensus rating of “Hold” and an average price target of $23.34.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.